BRIEF-Abivax Nets $920 Mln In Gross Proceeds From ADS Offering

Abivax SA Sponsored ADR

ABVX

0.00

July 2 (Reuters) - Abivax SA ABVX.PA:

ANNOUNCES FULL EXERCISE OF UNDERWRITERS’ OPTION TO PURCHASE ADDITIONAL ADSS, BRINGING GROSS PROCEEDS OF OFFERING TO $920M (€807M)
TOTAL 7.36 MILLION ADSS ISSUED; GROSS PROCEEDS $920 MILLION, NET PROCEEDS $874.1 MILLION
PROCEEDS TO BE USED FOR POTENTIAL COMMERCIALIZATION OF OBEFAZIMOD IN U.S. AND CLINICAL RESEARCH EXPENSES
ADDITIONAL ADSS EXPECTED TO BE DELIVERED WITH OFFERING CLOSING ON JULY 6, 2026

Source text: ID:nEQ8p4YVma

Further company coverage: ABVX.PA

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.